Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01783977 · ClinicalTrials.gov registry record · Phase 1
Evaluating the Safety and Immune Response to Three HIV Vaccine Schedules in Healthy, HIV-Uninfected Adults
A Phase 1 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 1
- Development phase
- 143
- Enrollment target
NCT01783977 is a Phase 1 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 143 participants.
The verdict
NCT01783977, a Phase 1 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 143 participants
- Enrollment target
Study Summary
NOTE: This study has stopped enrolling new participants, and all study vaccinations for currently enrolled participants have been stopped. Currently, there are no vaccines approved for the prevention of HIV infection, but there are many clinical trials taking place that are studying experimental HIV vaccines. The purpose of this study is to evaluate the safety and tolerability of three different HIV vaccine schedules in healthy, HIV-uninfected adults.
Interventions
- BIOLOGICAL DNA-HIV-PT123 vaccine
- BIOLOGICAL NYVAC-HIV-PT1 vaccine
- BIOLOGICAL NYVAC-HIV-PT4 vaccine
- BIOLOGICAL Placebo for DNA-HIV-PT123 vaccine
- BIOLOGICAL Placebo for NYVAC-HIV-PT1 vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 143 participants |
| Start Date | 2013-04 |
| Est. Completion | 2018-10-24 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01783977
The ClinicalTrials.gov registry entry for NCT01783977 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 143 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which DNA-HIV-PT123 vaccine is the first listed.
NCT01783977 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01783977 about?
NCT01783977 is a clinical study titled "Evaluating the Safety and Immune Response to Three HIV Vaccine Schedules in Healthy, HIV-Uninfected Adults". NOTE: This study has stopped enrolling new participants, and all study vaccinations for currently enrolled participants have been stopped. Currently, there are no vaccines approved for the prevention of HIV infection, but there are many clinical trials taking place that are studying experimental HI...
What is the current status of trial NCT01783977?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 143 participants. The study started on 2013-04. Estimated completion is 2018-10-24.
What interventions are being tested in trial NCT01783977?
The interventions under investigation include: DNA-HIV-PT123 vaccine (BIOLOGICAL), NYVAC-HIV-PT1 vaccine (BIOLOGICAL), NYVAC-HIV-PT4 vaccine (BIOLOGICAL), Placebo for DNA-HIV-PT123 vaccine (BIOLOGICAL), Placebo for NYVAC-HIV-PT1 vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT01783977?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.